Biosensors International (Booth 1456) is featuring clinical data forits BioMatrix Biolimus A9, its new bioresorbable drug-eluting stentplatform, which is not yet available in the U.S.

Boston Scientific (Booth 814) is highlighting various lectures,presentations and analyses of the recently released results of theSYNTAX trial.

CeloNova BioSciences (Booth 1408) is debuting the technology behind theCatania coronary stent system, which is only approved in Europe, featuring a NanoThinPolyzene-F surface treatment.

Invatec (Booth 1450) is launching U.S. operations for its peripheraltreatments for the coronary, carotid, renal and iliac arteries byshowcasing an array of its coronary and peripheral products, which arenot currently available for purchase in the U.S.

Medtronic (Booth 826) is featuring clinical research updates from itsinternational RESOLUTE trials, designed to assess the safety andefficacy of its Endeavor Resolute drug-eluting stent (DES) system,which is an investigational device in the U.S., but commerciallyavailable in Europe.

OrbusNeich Medical (Booth 1011) is highlighting data from clinical trials of its Genous bio-engineered R stent, which is not commercially available in the U.S., to prevent thrombosis and minimize restenosis.

InfraReDx (Booth 1414) is rolling out its LipiScan imaging system,which uses near-infrared (NIR) spectroscopy to identify lipidcore-containing plaques of interest in the coronary arteries inpatients undergoing cardiac catheterization.

GE Healthcare (Booth 638), in its foray to re-invent interventionalcardiology, is announcing new offerings in its collaboration withBiosense Webster, and new capabilities for its Innova series ofinterventional x-ray equipment.